Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

China: These 50 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "China: These 50 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ZTALMY (ganaxolone) generic drug versions launch in China?

Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: China Patent 106,667,918

ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in China?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: China Patent 105,012,303

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in China?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: China Patent 101,616,895

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in China?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: China Patent 102,317,268

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in China?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: China Patent 103,641,833

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in China?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: China Patent 101,389,338

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in China?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: China Patent 101,754,677
Patent Title: Method for preparing particles comprising metal oxide coating and particles with metal oxide coating

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in China?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: China Patent 101,646,420

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can LEXISCAN (regadenoson) generic drug versions launch in China?

Generic name: regadenoson
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 02, 2027
Generic Entry Controlled by: China Patent 101,379,073
Patent Title: Process for preparing an a2a-adenosine receptor agonist and its polymorphs

LEXISCAN is a drug marketed by Astellas. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LEXISCAN

See drug price trends for LEXISCAN.

The generic ingredient in LEXISCAN is regadenoson. Additional details are available on the regadenoson profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in China?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: China Patent 101,686,943

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in China?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: China Patent 103,933,555

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in China?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: China Patent 101,686,943

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in China?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: China Patent 103,933,555

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can SPRAVATO (esketamine hydrochloride) generic drug versions launch in China?

Generic name: esketamine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: China Patent 101,466,364
Patent Title: Intranasal administration of ketamine to treat depression

Drug Price Trends for SPRAVATO
SPRAVATO is a drug marketed by Janssen Pharms. There are seven patents protecting this drug. There has been litigation on patents covering SPRAVATO

See drug price trends for SPRAVATO.

The generic ingredient in SPRAVATO is esketamine hydrochloride. Additional details are available on the esketamine hydrochloride profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in China?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: China Patent 101,668,738

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in China?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: China Patent 104,211,624

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch in China?

Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: China Patent 101,677,961
Patent Title: Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent

Drug Price Trends for EDARBI
EDARBI is a drug marketed by Azurity. There is one patent protecting this drug. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. Additional details are available on the azilsartan kamedoxomil profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch in China?

Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 04, 2027
Generic Entry Controlled by: China Patent 102,276,606

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

The generic ingredient in VARUBI is rolapitant hydrochloride. Additional details are available on the rolapitant hydrochloride profile page.

When can INLYTA (axitinib) generic drug versions launch in China?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: China Patent 101,679,356

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can INLYTA (axitinib) generic drug versions launch in China?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: China Patent 103,626,739

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in China?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: China Patent 101,460,489
Patent Title: Modulators of atp-binding cassette transporters

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in China?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: China Patent 103,254,177
Patent Title: Modulators of atp-binding cassette transporters

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch in China?

Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: China Patent 101,657,829

Drug Price Trends for QVAR REDIHALER
QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. Additional details are available on the beclomethasone dipropionate profile page.

When can TRADJENTA (linagliptin) generic drug versions launch in China?

Generic name: linagliptin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 30, 2027
Generic Entry Controlled by: China Patent 101,437,493

Drug Price Trends for TRADJENTA
TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. Additional details are available on the linagliptin profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in China?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: China Patent 102,688,207

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in China?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: China Patent 102,697,745

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in China?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: China Patent 101,490,053

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in China?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: China Patent 103,435,595

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in China?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: China Patent 103,467,385

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in China?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: China Patent 101,679,315

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in China?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: China Patent 101,677,965

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in China?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: China Patent 101,677,959

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in China?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: China Patent 101,677,959

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in China?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: China Patent 101,932,582

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in China?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: China Patent 103,524,509

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch in China?

Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 15, 2027
Generic Entry Controlled by: China Patent 102,614,179
Patent Title: 1- [2- (2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment

Drug Price Trends for TRINTELLIX
TRINTELLIX is a drug marketed by Takeda Pharms Usa. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering TRINTELLIX

See drug price trends for TRINTELLIX.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. Additional details are available on the vortioxetine hydrobromide profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in China?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: China Patent 101,711,254
Patent Title: Synthetic bile acid composition, method, and preparation

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in China?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: China Patent 106,083,969
Patent Title: 合成胆汁酸组合物、方法和制剂 (Synthetic bile acid composition, method, and preparation)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in China?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: China Patent 106,146,594
Patent Title: 合成胆汁酸组合物、方法和制剂 (Synthetic bile acid composition, method, and preparation)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can CARDAMYST (etripamil) generic drug versions launch in China?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: China Patent 101,754,678
Patent Title: Short acting phenylalkylamine calcium channel blockers and uses thereof

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in China?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: China Patent 101,501,019
Patent Title: Short-acting benzodiazepine salts and their polymorphic forms

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in China?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: China Patent 103,288,834
Patent Title: Short-acting benzodiazepine salts and their polymorphic forms

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in China?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: China Patent 104,059,071
Patent Title: Short-acting Benzodiazepine Salts And Their Polymorphic Forms

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in China?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: China Patent 104,059,072
Patent Title: Short-acting Benzodiazepine Salts And Their Polymorphic Forms

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch in China?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: China Patent 101,541,320
Patent Title: Combination of adapalene and benzoyl peroxide for treating acne lesions

Drug Price Trends for EPIDUO
EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch in China?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: China Patent 101,541,320
Patent Title: Combination of adapalene and benzoyl peroxide for treating acne lesions

Drug Price Trends for EPIDUO FORTE
EPIDUO FORTE is a drug marketed by Galderma Labs. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in China?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: China Patent 101,687,857
Patent Title: Pyridazinone derivates

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in China?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: China Patent 101,743,241
Patent Title: Pyridazinone derivates

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in China?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: China Patent 101,801,351

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in China?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 01, 2027
Generic Entry Controlled by: China Patent 101,686,930

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can WINLEVI (clascoterone) generic drug versions launch in China?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: China Patent 101,743,316
Patent Title: Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in China?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: China Patent 103,450,304
Patent Title: Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in China?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: China Patent 104,861,023
Patent Title: 用于获得11‑脱氧皮醇的17α‑单酯和/或其9,11‑脱氢衍生物的酶法 (Enzymatic Process For Obtaining 17 Alpha-monoesters Of Cortexolone And/or Its 9,11-dehydroderivatives)

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in China?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: China Patent 101,861,152
Patent Title: DEHA compositions for treating menopause

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in China?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: China Patent 102,861,335
Patent Title: DHEA compositions for treating menopause

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in China?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: China Patent 105,412,121
Patent Title: DHEA compositions for treating menopause

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in China?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: China Patent 109,893,526
Patent Title: 治疗绝经期的DEHA组合物 (DHEA compositions for treating menopause)

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in China?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: China Patent 101,406,457

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in China?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: China Patent 101,820,859

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in China?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: China Patent 101,861,146
Patent Title: Pharmaceutical compositions

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in China?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: China Patent 104,688,702
Patent Title: PHARMACEUTICAL COMPOSITIONS

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in China?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: China Patent 106,619,710
Patent Title: 药物组合物 (Pharmaceutical compositions)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in China?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: China Patent 111,789,820
Patent Title: 药物组合物 (PHARMACEUTICAL COMPOSITIONS)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in China?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: China Patent 112,022,796
Patent Title: 药物组合物 (Pharmaceutical compositions)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in China?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: China Patent 112,022,821
Patent Title: 药物组合物 (Pharmaceutical compositions)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in China?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: China Patent 112,022,822
Patent Title: 药物组合物 (Pharmaceutical compositions)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in China?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: China Patent 103,641,816

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in China?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: China Patent 101,868,472
Patent Title: Antibacterial aminoglycoside analogs

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in China?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: China Patent 103,360,440
Patent Title: 抗菌性氨基糖苷类似物 (Antibacterial aminoglycoside analogs)

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in China?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 102,186,827

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in China?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 102,186,832

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in China?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 102,643,241

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in China?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 103,819,419

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in China?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 102,186,827

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in China?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 102,186,832

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in China?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 102,643,241

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in China?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: China Patent 103,819,419

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in China?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2027
Generic Entry Controlled by: China Patent 101,547,904

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in China?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: China Patent 102,006,890
Patent Title: Targeting lipids

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in China?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: China Patent 101,631,464
Patent Title: Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in China?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: China Patent 105,254,634
Patent Title: SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in China?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: China Patent 108,774,232
Patent Title: 2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 (2,3-dihydroimidazo[1,2-c]quinazoline Derivatives)

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in China?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: China Patent 115,724,847
Patent Title: 2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 (2, 3-dihydroimidazo [1, 2-c] quinazoline substituted derivatives)

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in China?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: China Patent 101,910,156

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in China?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: China Patent 103,626,744

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORENITRAM (treprostinil diolamine) generic drug versions launch in China?

Generic name: treprostinil diolamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2027
Generic Entry Controlled by: China Patent 101,903,324
Patent Title: Process to prepare treprostinil, the active ingredient in Remodulin

ORENITRAM is a drug marketed by United Therap. There are nine patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering ORENITRAM

See drug price trends for ORENITRAM.

The generic ingredient in ORENITRAM is treprostinil diolamine. Additional details are available on the treprostinil diolamine profile page.

When can ORENITRAM (treprostinil diolamine) generic drug versions launch in China?

Generic name: treprostinil diolamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2027
Generic Entry Controlled by: China Patent 103,274,926
Patent Title: 种制备Remodulin中的活性成分曲前列素的改良方法 (An improved process to prepare treprostinil, the active ingredient in Remodulin)

ORENITRAM is a drug marketed by United Therap. There are nine patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering ORENITRAM

See drug price trends for ORENITRAM.

The generic ingredient in ORENITRAM is treprostinil diolamine. Additional details are available on the treprostinil diolamine profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in China?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: China Patent 101,932,327

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in China?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: China Patent 105,560,176

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can RYTARY (carbidopa; levodopa) generic drug versions launch in China?

Generic name: carbidopa; levodopa
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 28, 2027
Generic Entry Controlled by: China Patent 101,910,113
Patent Title: Controlled release formulations of levodopa and uses thereof

RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering RYTARY

See drug price trends for RYTARY.

The generic ingredient in RYTARY is carbidopa; levodopa. Additional details are available on the carbidopa; levodopa profile page.

When can SOLUPREP (chlorhexidine gluconate; isopropyl alcohol) generic drug versions launch in China?

Generic name: chlorhexidine gluconate; isopropyl alcohol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 31, 2027
Generic Entry Controlled by: China Patent 101,951,779
Patent Title: Antimicrobial compositions

SOLUPREP is a drug marketed by Solventum.

The generic ingredient in SOLUPREP is chlorhexidine gluconate; isopropyl alcohol. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

When can SOLUPREP (chlorhexidine gluconate; isopropyl alcohol) generic drug versions launch in China?

Generic name: chlorhexidine gluconate; isopropyl alcohol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 31, 2027
Generic Entry Controlled by: China Patent 107,019,686
Patent Title: 抗微生物组合物 (Antimicrobial compositions)

SOLUPREP is a drug marketed by Solventum.

The generic ingredient in SOLUPREP is chlorhexidine gluconate; isopropyl alcohol. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

China Branded and Generic Drug Markets: Regulatory Opportunities, Patent Risks, and Market Access Assessment

Last updated: October 17, 2026

China’s pharmaceutical market is shifting from volume-driven generic growth toward quality-based competition, centralized procurement, innovative medicines, and domestic manufacturing. Generic drugs remain the largest market segment by unit volume, while branded innovative drugs and high-quality generics are gaining value share through National Reimbursement Drug List access and hospital procurement. The main commercial opportunities are China localization, oncology and specialty medicines, biosimilars, complex generics, contract development and manufacturing, and licensing. The main barriers are price erosion, centralized procurement, regulatory localization, patent linkage disputes, reimbursement delays, and provincial market fragmentation.

How large is China’s branded and generic drug market?

China is the world’s second-largest pharmaceutical market after the United States. The market has two distinct structures:

Segment Primary demand channel Competitive basis Main commercial risk
Innovative branded drugs Tertiary hospitals, specialty clinics, commercial insurance, NRDL Clinical value, reimbursement, local trials, price negotiation Reimbursement price cuts and rapid domestic competition
Originator off-patent drugs Hospitals, pharmacies, public procurement Brand reputation, quality, supply reliability Generic substitution and centralized procurement
Conventional generics Hospitals, retail pharmacies, procurement platforms Lowest sustainable price, quality compliance Severe price erosion and volume displacement
High-quality generics Hospitals, national and provincial procurement Bioequivalence, consistency evaluation, supply Loss of preferred status if competitors pass evaluation
Biosimilars Hospitals and specialist centers Price, interchangeability perception, manufacturing scale Tender discounts and physician adoption
Complex generics Hospitals, specialty channels Technical barriers, device or formulation differentiation Regulatory complexity and patent litigation

China’s generic sector is still dominant by volume because public hospitals account for a large portion of prescription drug demand and many products have reached patent expiry. Value growth is increasingly concentrated in innovative medicines, oncology, immunology, diabetes, rare diseases, vaccines, and specialty products.

The National Medical Products Administration, or NMPA, is the principal drug regulator. The National Healthcare Security Administration, or NHSA, controls reimbursement negotiations, centralized procurement, and much of the economic access environment.

What is the regulatory status of branded and generic drugs in China?

China uses a marketing authorization holder, or MAH, system. The MAH may be a domestic company or an eligible overseas applicant with a qualified Chinese legal representative. The system separates marketing authorization from manufacturing ownership and permits contract manufacturing under regulatory controls.

Key regulatory pathways include:

Product type Regulatory pathway Core evidence
New chemical drug NMPA new drug application Quality, nonclinical, clinical and manufacturing data
Imported innovative drug Imported drug application or applicable domestic registration pathway Overseas and China-relevant clinical and quality data
Generic chemical drug Generic application Pharmaceutical equivalence, quality, and often bioequivalence data
Generic with reference product Registration plus consistency evaluation Bioequivalence or therapeutic equivalence against the reference listed drug
Biosimilar Biologic application pathway Analytical comparability, pharmacology, immunogenicity and clinical evidence
Traditional Chinese medicine Product-specific pathway Quality, safety, efficacy and traditional-use evidence depending on classification
OTC drug OTC registration or conversion pathway Safety, efficacy, quality and labeling evidence

The NMPA has accelerated review pathways for innovative drugs, urgently needed medicines, rare-disease therapies, pediatric products, breakthrough therapies, and products with significant clinical value. The regulator also accepts certain overseas clinical data, subject to data integrity, population relevance, and inspection requirements.

China’s regulatory environment has moved closer to International Council for Harmonisation standards, but local execution remains critical. Applicants must manage Chinese-language submissions, domestic pharmacovigilance obligations, local inspection risks, import logistics, clinical-trial requirements, and post-approval change controls.

How do generic drug approvals work in China?

A conventional generic applicant must demonstrate quality and therapeutic comparability to an accepted reference listed drug. For many oral solid products, bioequivalence is central. Products that pass consistency evaluation receive stronger access to public hospital procurement and are more likely to qualify for national centralized procurement.

Consistency evaluation has changed the competitive structure. Before the reform, many approved generics had uncertain quality comparability and competed through distribution relationships. After evaluation, procurement increasingly favors products with demonstrated equivalence, reliable supply, and low prices.

Generic applicants face four commercial tests:

  1. Whether an accepted reference listed drug exists.
  2. Whether the applicant can meet Chinese quality and manufacturing standards.
  3. Whether the product can pass consistency evaluation.
  4. Whether the applicant can remain profitable after centralized procurement.

Passing regulatory review does not guarantee commercial success. A product may receive approval but fail to secure hospital volume because another supplier offers a lower price, has broader provincial coverage, or has stronger production capacity.

What are the opportunities for high-quality generics?

High-quality generics have opportunities in products with:

  • Expiring or expired composition patents.
  • Limited competition after consistency evaluation.
  • High hospital usage and stable clinical demand.
  • Supply shortages or unreliable originator production.
  • Complex dosage forms that deter low-cost entrants.
  • Established reference products with clear bioequivalence pathways.
  • Large markets excluded from the first rounds of centralized procurement.

The strongest opportunities are usually not basic immediate-release tablets with many approved suppliers. They are products with technical manufacturing requirements, sterile production, modified release, inhalation delivery, injectable formulations, ophthalmic delivery, or difficult-to-source reference products.

What is China’s patent linkage system?

China has a patent information registration platform for approved drugs. Patent holders can register relevant patents covering active ingredients, formulations, compositions, or approved methods of use. The system is commonly described as China’s patent linkage framework.

A generic applicant must make a patent declaration when seeking approval for a product associated with a listed patent. The declarations generally identify whether:

  • No relevant patent is listed.
  • The patent has expired.
  • The applicant will wait until patent expiry.
  • The applicant believes the patent is invalid or will not be infringed.

A patent challenge can trigger a stay period for regulatory approval under China’s patent linkage provisions. The stay is designed to allow patent litigation or adjudication before commercial approval, although the precise effect depends on the product, declaration, patent status, and procedural timing.

China’s framework differs from the U.S. Hatch-Waxman system. Patent listing, declaration, litigation, regulatory review, and court procedures do not map perfectly to U.S. Orange Book or Paragraph IV practice. Companies should analyze the Chinese patent registry, patent family, claim scope, validity, prosecution history, regulatory filing status, and litigation record separately.

How strong are branded drug patent estates in China?

Patent strength depends on more than the nominal expiry date. A commercial patent estate may include:

Patent category Typical protection Commercial relevance
Composition-of-matter patent Active pharmaceutical ingredient Usually the strongest barrier
Salt, polymorph or crystalline-form patent Specific chemical form Can delay some generic approaches
Formulation patent Release profile, excipients, delivery system Relevant to modified-release and injectable products
Method-of-use patent Disease, patient population or dosing regimen Depends on enforceability and generic labeling
Combination patent Use with another active ingredient Relevant in oncology and infectious disease
Manufacturing patent Process, purification or intermediate More relevant to supply-chain control than ordinary market exclusivity
Device patent Injector, pen, inhaler or delivery system Important for biologics and combination products

A branded product with only a weak method-of-use patent may face earlier generic competition than a product with a valid composition patent. Conversely, a complex formulation or device can create practical barriers after the principal active-ingredient patent expires.

Patent term adjustment and patent term extension rules should be assessed product by product. Regulatory delay compensation may be available in defined circumstances, but the benefit is not equivalent to automatic U.S.-style patent term restoration for every product.

When do China branded drugs lose exclusivity?

There is no single exclusivity date for a branded drug in China. Market protection may end through several overlapping events:

  1. Expiration or invalidation of the key composition patent.
  2. Expiration of formulation and other relevant patents.
  3. Completion of any applicable regulatory data-protection period.
  4. Approval of a generic or biosimilar competitor.
  5. Loss of reimbursement preference after NRDL negotiation.
  6. Inclusion in centralized procurement.
  7. Physician substitution following consistency evaluation.

Chemical drug exclusivity is generally patent-led. China does not provide a broad, universal small-molecule data-exclusivity period equivalent to the United States’ five-year new chemical entity period. Regulatory protection is narrower and depends on product classification, regulatory rules, and applicable international commitments.

For biologics, the practical exclusivity period is also driven by patents, clinical complexity, manufacturing capability, and physician acceptance. China does not operate a simple, fixed statutory biologic exclusivity period equivalent to the U.S. 12-year framework.

What is China’s Orange Book status?

China maintains a national drug information platform that records approved drug products and related patent information. It is commonly referred to as the China Drug Patent Information Registration Platform. The platform supports patent declarations and generic-drug review under the linkage system.

Its commercial functions include:

  • Identifying patents asserted against a listed drug.
  • Reviewing generic applicants’ patent declarations.
  • Supporting patent disputes before generic approval.
  • Improving visibility into formulation and method-of-use patents.
  • Helping originators monitor potential generic entry.

The platform does not eliminate the need for independent patent analysis. Patent owners may fail to list a relevant patent, list a patent with limited enforceability, or face challenges based on claim construction, validity, enablement, or infringement.

How do centralized procurement and NRDL negotiations affect drug prices?

China’s healthcare market is heavily shaped by public procurement and reimbursement. The NHSA uses two main mechanisms:

  • National centralized procurement, which selects products primarily through competitive bidding.
  • National Reimbursement Drug List negotiations, which reduce prices in exchange for reimbursement access.

Centralized procurement has produced substantial price reductions, particularly for high-volume generics with multiple approved suppliers. Products that win may gain large volumes, while losing suppliers can experience sharp hospital-access declines.

NRDL negotiations affect innovative drugs differently. A branded product may obtain rapid reimbursement and broad access but accept a steep price discount. The commercial calculation depends on the tradeoff between:

  • Expected reimbursed volume.
  • Price reduction.
  • Hospital adoption.
  • Competitive pipeline.
  • Out-of-pocket affordability.
  • Private insurance and commercial channel potential.

A product outside the NRDL may retain a higher list price but face limited public-hospital uptake. A product inside the NRDL may achieve much larger volume at a lower net price.

What are the main regulatory opportunities in China?

Domestic licensing and co-development

Foreign companies can license China rights to local pharmaceutical companies with regulatory, commercial, and hospital-access capabilities. Transactions may include:

  • Upfront payments.
  • Development milestones.
  • Regulatory milestones.
  • Sales milestones.
  • Tiered royalties.
  • Manufacturing rights.
  • China-only or broader Asia-Pacific rights.

Local partners can reduce execution risk but may demand control over registration, pricing, manufacturing, and reimbursement strategy.

Local manufacturing and supply-chain localization

China-based production can improve supply reliability, reduce import dependency, support tender participation, and simplify certain regulatory interactions. Localization is most valuable for products facing:

  • High import costs.
  • Cold-chain complexity.
  • Supply shortages.
  • Large centralized-procurement demand.
  • Hospital requirements for dependable delivery.
  • Government preference for domestic supply resilience.

The risks include technology leakage, quality-system exposure, transfer failure, and difficulty enforcing manufacturing and know-how rights.

Biosimilars and complex biologics

China has a substantial biologics manufacturing base and a large patient population. Opportunities include monoclonal antibodies, insulin products, oncology biologics, autoimmune therapies, and follow-on biologics. Competitive advantage depends on analytical comparability, process consistency, immunogenicity control, scale, and hospital access.

Biosimilar pricing can be materially lower than originator pricing, but clinical adoption depends on physician confidence and procurement status. Manufacturing know-how may be more important than the nominal patent expiry date.

Specialty generics

Specialty generics can avoid some of the extreme price competition affecting simple oral solids. Areas with potential include injectable oncology products, inhaled products, ophthalmics, extended-release medicines, and products requiring device integration.

The regulatory burden is higher. Applicants must control formulation reproducibility, container-closure systems, device performance, sterility, extractables and leachables, and stability.

What regulatory challenges face foreign pharmaceutical companies?

Foreign companies face five major challenges.

Local clinical and evidence requirements

China may accept overseas data, but the evidence must support Chinese registration and patient relevance. Bridging studies, local pharmacokinetic data, or China participation in global trials may still be needed.

Regulatory and manufacturing inspections

The NMPA can inspect overseas manufacturing sites and review data integrity, quality systems, electronic records, deviation management, and supply controls. Inspection findings can delay approval or restrict supply.

Reimbursement and pricing pressure

Regulatory approval does not establish market access. NRDL negotiation and centralized procurement can reduce net prices rapidly. Companies must model net revenue rather than headline list price.

Patent and data exposure

A China filing creates local patent, regulatory, manufacturing, and disclosure obligations. Patent claims drafted for the United States or Europe may not provide equivalent protection in China. Local prosecution and enforcement strategy must begin early.

Distribution and hospital access

China’s hospital market is dispersed across national, provincial, and institutional decision-making. Distributor quality, tender execution, medical affairs, pharmacovigilance, and inventory management can determine whether an approved product reaches patients.

Which companies are positioned in China’s branded and generic markets?

China’s competitive landscape includes:

  • Large domestic pharmaceutical groups with broad hospital networks.
  • Specialized generic manufacturers with strong procurement capabilities.
  • Innovative Chinese biotechnology companies.
  • Multinational pharmaceutical companies with established regulatory operations.
  • Contract development and manufacturing organizations.
  • Regional distributors and commercial platform companies.

Domestic firms generally have advantages in local procurement, hospital relationships, manufacturing cost, and regulatory execution. Multinational companies often retain advantages in global clinical development, complex biologics, high-value brands, and quality systems. The gap is narrowing in oncology, immunology, vaccines, cell therapy, and advanced manufacturing.

Competition is increasingly based on execution rather than approval alone. A company that cannot sustain supply, pass inspection, manage tenders, and defend its patent position may lose commercial value despite strong clinical data.

What generic entry risks exist for branded products?

Branded products face the highest generic-entry risk when they have:

  • An expired composition patent.
  • Multiple approved reference-equivalent products.
  • No enforceable formulation or use patents.
  • High volume and transparent clinical demand.
  • An active centralized-procurement category.
  • Simple manufacturing.
  • Limited physician loyalty.
  • No meaningful delivery-system differentiation.

Risk is lower when the product has:

  • A surviving composition or crystalline-form patent.
  • A difficult-to-replicate formulation.
  • Device or delivery integration.
  • Sterile or complex manufacturing.
  • Limited reference-product availability.
  • Strong clinical differentiation.
  • An orphan or specialty indication.
  • A manufacturing process that is difficult to reproduce economically.

Generic entry can occur in stages: regulatory approval, tender participation, hospital listing, procurement win, and actual patient substitution. Each stage has a different probability and timing.

How does China compare with the United States and Europe?

Issue China United States Europe
Primary regulator NMPA FDA National agencies and EMA
Generic pathway Generic application and consistency evaluation ANDA National, decentralized or centralized procedures
Patent linkage Drug patent information platform and declarations Orange Book and Hatch-Waxman National systems with limited harmonization
Price control Strong NHSA and centralized procurement influence Commercial negotiation and payer-specific pricing National and regional health technology assessment
Biosimilar framework NMPA technical guidance and approval pathway FDA biosimilar pathway EMA-developed biosimilar framework
Hospital access Strong public-hospital and tender influence Fragmented payer and provider system National reimbursement and procurement systems
Commercial entry risk Price cuts plus procurement displacement Patent litigation and payer substitution Reimbursement, reference pricing and national tenders

China presents faster volume expansion opportunities than many mature markets, but price and procurement risk are also more concentrated.

What litigation and settlement issues should companies monitor?

Companies should monitor:

  • Patent infringement complaints by originators.
  • Generic declaratory or invalidity actions.
  • Patent linkage stay periods.
  • Administrative patent invalidation proceedings.
  • Trade-secret and manufacturing-process disputes.
  • Trademark and packaging disputes.
  • Licensing settlement terms affecting launch timing.
  • Antitrust scrutiny of settlement or distribution arrangements.

Settlement agreements must account for Chinese competition law, regulatory independence, patent validity, launch rights, supply commitments, and confidentiality. A settlement that delays entry may face scrutiny if it restricts competition beyond the patent’s legitimate scope.

Key Takeaways

  • China remains a large generic market, but centralized procurement has made simple generics structurally low-margin.
  • Innovative branded drugs can achieve scale through NRDL access, but reimbursement negotiations impose substantial price reductions.
  • NMPA approval is only the first commercial milestone. Procurement, reimbursement, hospital access, and supply reliability determine revenue.
  • China’s patent linkage system requires early review of composition, formulation, method-of-use, device, and manufacturing patents.
  • High-quality generics, complex formulations, specialty injectables, biosimilars, and localized manufacturing offer stronger opportunities than undifferentiated tablets.
  • Foreign companies need local regulatory, manufacturing, reimbursement, and commercial capabilities.
  • Patent expiry alone does not determine generic entry. Consistency evaluation, tender timing, supply capacity, and hospital substitution are equally important.
  • Licensing and co-development with Chinese companies can accelerate access but require careful control of data, manufacturing know-how, patents, and commercialization rights.

FAQs

Is China a better market for branded drugs or generics?

China offers greater unit volume for generics, while branded innovative drugs have stronger value-growth potential. Generics face severe pricing pressure, whereas innovative drugs face NRDL discounts and local competition.

Does China have a five-year generic exclusivity period?

China does not provide a universal small-molecule exclusivity period equivalent to the U.S. five-year new chemical entity framework. Commercial protection is primarily patent-based, with narrower regulatory protections in defined circumstances.

Can a foreign company sell drugs in China without a local partner?

A foreign company may hold a marketing authorization under China’s MAH system, but local legal representation, regulatory operations, distribution, pharmacovigilance, and market-access infrastructure remain necessary.

Are Chinese biosimilars interchangeable with originator biologics?

Regulatory approval establishes biosimilarity under the applicable NMPA pathway. Automatic substitution and practical interchangeability depend on regulatory policy, institutional practice, physician acceptance, procurement rules, and product-specific evidence.

What is the biggest risk to China pharmaceutical revenue forecasts?

The largest risk is overestimating price retention. NRDL negotiation, centralized procurement, competitor approval, provincial tender outcomes, and hospital substitution can reduce net revenue even when demand remains strong.

References

  1. National Medical Products Administration. (2020). Drug administration law of the People’s Republic of China and implementing regulations. Beijing, China: NMPA.

  2. National Medical Products Administration. (2023). Technical guidelines for the research and evaluation of chemical generic drugs. Beijing, China: NMPA.

  3. National Healthcare Security Administration. (2023). National reimbursement drug list and national centralized procurement policies. Beijing, China: NHSA.

  4. State Council of the People’s Republic of China. (2017). Opinions on deepening the reform of the review and approval system for drugs and medical devices. Beijing, China: State Council.

  5. World Health Organization. (2022). China pharmaceutical system and regulatory assessment materials. Geneva, Switzerland: WHO.

  6. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2023). ICH guidelines and China implementation status. Geneva, Switzerland: ICH.

  7. National Intellectual Property Administration. (2023). Patent law of the People’s Republic of China and implementing regulations. Beijing, China: CNIPA.

  8. National Medical Products Administration. (2021). Measures for the implementation of early resolution mechanisms for drug patent disputes. Beijing, China: NMPA.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.